Bavarian, mpox vaccine
Business Insider · 1d
Bavarian Nordic Gets EMA Approval Of Mpox Vaccine For Adolescents
(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX smallpox and mpox vaccine. This extends the current marketing authorization to include adolescents 12 to 17 years of age.
YAHOO!Finance · 1d
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger population COPENHAGEN,
devdiscourse · 1d
EU Approves Use of Bavarian Nordic's Mpox Vaccine for Adolescents
Bavarian Nordic's mpox vaccine has gained approval for use in adolescents by the EU's drug regulator. This move is seen as essential for containing an outbreak in parts of Africa, with the World Health Organization declaring mpox a global public health emergency.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results